Citations

Showing 10 of 108162 citations.

Kartagener’s Syndrome
Zurcher, Kenneth S. , Zurcher, Kenneth , Kawashima, Akira

Mayo Clinic

New England Journal of Medicine | March 20, 2021 | Volume: 384 | Issue: 12 | Pages: No page available

10.1056/nejmicm2028152 | PMID 33764707 Get It

Comments on: Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein
Naddaf, Elie , Kourelis, Taxiarchis , Naddaf, Elie

Mayo Clinic

International Journal of Cancer | March 20, 2021 | Volume: 149 | Issue: 3 | Pages: 741-742

10.1002/ijc.33572 | PMID 33742684 Get It

Reply to: Comments on: Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein
Kotchetkov, Rouslan , Susman, David , Bhutani, Divaya , Broch, Kaspar , Bhutani, Divaya , Dispenzieri, Angela , Buadi, Francis K.

Mayo Clinic

International Journal of Cancer | March 20, 2021 | Volume: 149 | Issue: 3 | Pages: 743-744

10.1002/ijc.33571 | PMID 33742687 Get It

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
Long, Millie D. , Reinisch, Walter , Loftus, Edward V. , Nduaka, Chudy I., Soonasra, Arif, Mundayat, Rajiv , Lawendy, Nervin, Chan, Gary , Friedman, Gary S. , Su, Chinyu , Loftus, Edward V , Sands, Bruce E , Reinisch, Walter , Panés, Julián

Mayo Clinic

Inflammatory Bowel Diseases | March 20, 2021 | Volume: 28 | Issue: 2 | Pages: 234-245

10.1093/ibd/izab056 | PMID 33742652 Get It

Abstract Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We present integrated analyses of nonmelanoma skin cancer (NMSC) incidence in the tofacitinib UC clinical program. Methods Nonmelanoma skin cancer events were evaluated from 3 randomized, placebo-controlled studies: 2 identical, 8-week induction studies (NCT01465763, NCT01458951), a 52-week maintenance study (NCT01458574), and an open-label, long-term extension study (NCT01470612). Cohorts analyzed were: Induction, Maintenance, and Overall (patients receiving ≥1 dose of tofacitinib 5 mg or 10 mg twice daily [BID]). An independent adjudication committee reviewed potential NMSC. Proportions and incidence rates (IRs; unique patients with events per 100 patient-years of exposure) for NMSC were evaluated. A Cox proportional hazards model was used for risk factor analysis. Results Nonmelanoma skin cancer was evaluated for 1124 patients (2576.4 patient-years of tofacitinib exposure; ≤6.8 years’ treatment). In the Induction Cohort, NMSC IR was 0.00 for placebo and 1.26 for 10 mg BID. Nonmelanoma skin cancer IR was 0.97 for placebo, 0.00 for 5 mg BID and 1.91 for 10 mg BID in the Maintenance Cohort, and 0.73 (n = 19) in the Overall Cohort. No NMSC was metastatic or led to discontinuation. In the Overall Cohort, Cox regression identified prior NMSC (hazard ratio [HR], 9.09; P = 0.0001), tumor necrosis factor inhibitor (TNFi) failure (3.32; P = 0.0363), and age (HR per 10-year increase, 2.03; P = 0.0004) as significant independent NMSC risk factors. Conclusions For patients receiving tofacitinib, NMSC occurred infrequently. Older age, prior NMSC, and TNFi failure, which are previously reported NMSC risk factors in patients with UC, were associated with increased NMSC risk.
Skin cancer in non‐white liver transplant recipients: Mayo Clinic experience
Tolaymat, Leila , Reimer, Danielle , Feig, Joshua, Gillis, Melinda S. , Speicher, Leigh L. , Haga, Claire , Gabriel, Emmanuel , Heckman, Michael G. , Yin, Mingyuan , Fosko, Scott W. , Dawson, Nancy L. , Tolaymat, Leila M , Reimer, Danielle K , Haga, Claire B , Gabriel, Emmanuel M , Keaveny, Andrew P , Dawson, Nancy L , Heckman, Michael G , Keaveny, Andrew P.

Mayo Clinic

International Journal of Dermatology | March 20, 2021 | Volume: 60 | Issue: 8 | Pages: 986-990

10.1111/ijd.15519 | PMID 33742703 Get It

Abstract Background Limited data are available on the development of skin cancer and the associated risk factors for non‐White liver transplant (LT) recipients. The aim of this study is to determine the incidence of newly diagnosed skin cancer postoperatively and to identify the risk factors for the development of skin cancer in non‐White LT recipients. Methods We conducted an initial retrospective chart review of non‐White LT patients who received a transplant at our center between January 1, 2011, and December 31, 2013. Results Of the 96 patients in the study cohort, 32% were Black, 17% were Asian, 15% were White Hispanic, and 10% were Black Hispanic. One patient had a history of nonmelanoma skin cancer before transplant. No skin cancers were diagnosed during follow‐up (median, 1.3 years; range, 17 days to 8.6 years). Conclusion Our center’s experience is consistent with the literature and suggests that the incidence of newly diagnosed skin cancer in non‐White liver transplant recipients is low. Longer follow‐up may provide additional insights into the specific risk factors for the posttransplant development of skin cancer.
Autoimmune encephalopathies presenting as dementia of subacute onset and rapid progression
Banks, Samantha A. , Sechi, Elia , Flanagan, E P , Sechi, Elia , Banks, Samantha , Flanagan, Eoin P.

Mayo Clinic

Therapeutic Advances in Neurological Disorders | March 20, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1756286421998906 | PMID 33796145 Get It

The terms autoimmune dementia and autoimmune encephalopathy may be used interchangeably; autoimmune dementia is used here to emphasize its consideration in young-onset dementia, dementia with a subacute onset, and rapidly progressive dementia. Given their potential for reversibility, it is important to distinguish the rare autoimmune dementias from the much more common neurodegenerative dementias. The presence of certain clinical features [e.g. facio-brachial dystonic seizures that accompany anti-leucine-rich-glioma-inactivated-1 (LGI1) encephalitis that can mimic myoclonus] can be a major clue to the diagnosis. When possible, objective assessment of cognition with bedside testing or neuropsychological testing is useful to determine the degree of abnormality and serve as a baseline from which immunotherapy response can be judged. Magnetic resonance imaging (MRI) head and cerebrospinal fluid (CSF) analysis are useful to assess for inflammation that can support an autoimmune etiology. Assessing for neural autoantibody diagnostic biomarkers in serum and CSF in those with suggestive features can help confirm the diagnosis and guide cancer search in paraneoplastic autoimmune dementia. However, broad screening for neural antibodies in elderly patients with an insidious dementia is not recommended. Moreover, there are pitfalls to antibody testing that should be recognized and the high frequency of some antibodies in the general population limit their diagnostic utility [e.g., anti-thyroid peroxidase (TPO) antibodies]. Once the diagnosis is confirmed, both acute and maintenance immunotherapy can be utilized and treatment choice varies depending on the accompanying neural antibody present and the presence or absence of cancer. The target of the neural antibody biomarker may help predict treatment response and prognosis, with antibodies to cell-surface or synaptic antigens more responsive to immunotherapy and yielding a better overall prognosis than those with antibodies to intracellular targets. Neurologists should be aware that autoimmune dementias and encephalopathies are increasingly recognized in novel settings, including post herpes virus encephalitis and following immune-checkpoint inhibitor use.
Accuracy of Noninvasive Blood Pressure Versus Central Aortic Pressure in Patients Supported on Left Ventricular Assist Device Therapy
Rosenbaum, Andrew , Clavell, Alfredo L. , Stulak, John M., Behfar, Atta , Rosenbaum, Andrew N , Behfar, Atta

Mayo Clinic

ASAIO Journal | March 20, 2021 | Volume: 67 | Issue: 8 | Pages: e134-e136

10.1097/mat.0000000000001418 | PMID 33741784 Get It

Kidney Allograft and Recipient Survival After Heart Transplantation by Induction Type in the United States
Riad, Samy , Alexy, Tamás , Jackson, Scott , Goswami, Umesh , Martin, Cindy M. , Riad, Samy M. , Goswami, Umesh

Mayo Clinic

Transplantation | March 20, 2021 | Volume: 106 | Issue: 3 | Pages: 633-640

10.1097/tp.0000000000003758 | PMID 33741841 Get It

Background. Induction choices for kidney-after-heart transplant recipients are variable. We examined the impact of kidney induction types on kidney graft and patient survival in heart transplant recipients. Methods. We analyzed the Scientific Registry of Transplant Recipient database from inception through the end of 2018 to study kidney and patient outcomes in the United States after heart transplantation. We only included recipients who were discharged on tacrolimus and mycophenolate maintenance. We grouped recipients by induction type into 3 groups: depletional (N = 307), nondepletional (n = 253), and no-induction (steroid only) (n = 57). We studied patients and kidney survival using Cox PH regression, with transplant centers included as a random effect. We adjusted the models for heart induction, recipient and donor age, gender, time between heart and kidney transplant, heart transplant indication, HLA mismatches, payor, live-donor kidney, transplant year, dialysis status, and diabetes mellitus at the time of kidney transplant. Results. The 1-y kidney rejection rates and creatinine levels were similar in all groups. The 1-y rehospitalization rate was higher in the depletional group (51.7%) and nondepletional group (50.7%) than in the no-induction group (39.1%) although this was not statistically significant. There were no differences in recipient or kidney survival by kidney induction type. Live-donor kidney was associated with improved patient (hazard ratio, 0.74; 95% confidence interval, 0.54-1.0; P = 0.05) and kidney survival (hazard ratio, 0.45; 95% confidence interval, 0.24-0.84; P = 0.012]. Conclusions. Type of kidney induction did not influence patient or kidney graft survival in heart transplant recipients. No-induction may be the preferred choice due to the lack of clinical benefits associated with induction use.
Anatomical Step-by-Step Dissection of Complex Skull Base Approaches for Trainees: Surgical Anatomy of the Middle Fossa Approaches and Anterior Petrosectomy, Surgical Principles, and Illustrative Cases
Salgado-López, Laura , Perry, Avital , Graffeo, Christopher S. , Carlstrom, Lucas P. , Leonel, Luciano, Driscoll, Colin L. W., Link, Michael J. , Peris‐Celda, Maria , Leonel, Luciano César Pereira Campos

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | March 20, 2021 | Volume: 83 | Issue: S 02 | Pages: e232-e243

10.1055/s-0041-1725030 | PMID 35832967 Get It

Abstract Introduction The middle fossa (MF) approaches encompass a group of versatile surgical accesses to pathologies in the MF, internal auditory canal (IAC), and superomedial aspect of the posterior fossa. Although many descriptions of the MF approaches have been published, a practical surgical guide that allows an easy understanding for Skull Base trainees is needed. Methods Three formalin-fixed, colored-injected specimens were dissected under microscopic magnification (six sides). A MF craniotomy followed by IAC drilling was performed on three sides, and anterior petrosectomy (AP) was performed in the remaining three sides. The anatomical dissection was documented in stepwise three-dimensional photographic images. Following dissection, representative case applications were reviewed. Results The MF approach provides direct access to the MF structures and IAC. The AP provides excellent access to the superomedial aspect of the posterior fossa. Key common steps include: positioning and skin incision; scalp and muscle flaps; burr holes; craniotomy flap elevation; dural dissection along the petrous ridge; division of the middle meningeal artery; and exposure of the greater superficial petrosal nerve, tegmen tympani, and V3. Then, to approach the IAC: superior IAC drilling, and longitudinal dura opening. The area drilled in the AP approach forms a pentagon limited by the petrous internal carotid artery, cochlea, IAC, petrous ridge, and lateral border of V3. Conclusion The MF approaches are challenging. Operatively oriented skull base dissections provide a crucial foundation for learning these techniques. We describe comprehensive step-by-step approaches intended to develop familiarity in the cadaver laboratory and facilitate understanding of their potential for skull base disorders. Basic surgical principles are described to help in the operating room as well as illustrative cases.
The Use of Mobile Technology in Audiology: Transforming Clinical Practice with Smartphones
McCaslin, Devin L.

Mayo Clinic

Journal of the American Academy of Audiology | March 19, 2021 | Volume: 31 | Issue: 10 | Pages: 699-700

10.1055/s-0041-1723790 | PMID 33740820 Get It